Immune Regulator Retinoic Acid-Inducible Gene I (RIG-I) in the Pathogenesis of Cardiovascular Disease.

Hao Wang, Jie Yin, Xinyan Gu, Wenhui Shao, Zhanjun Jia, Hongbing Chen, Weiwei Xia

Journal: Frontiers in immunology 2022;13():893204

PMID: 35693778

Abstract

Retinoic acid-inducible gene I (RIG-I) is a cytosolic pattern recognition receptor that contains two CARD domains, an RNA helicase domain, and a C-terminal domain. RIG-I initiates antiviral innate immunity by recognizing exogenous viral RNAs/DNAs. However, some studies have reported that RIG-I activation leads to damage in various organs and tissues in diverse circumstances. Recent studies have shown that RIG-I is involved in cancer, lupus nephritis, immunoglobulin A nephropathy, Crohn's disease, and atherosclerosis. These reports indicate that RIG-I not only participates in antiviral signaling pathways but also exerts an influence on non-viral infectious diseases. RIG-I is widely expressed in immune and non-immune cells including smooth muscle cells, endothelial cells, and cardiomyocytes. A succinct overview of RIG-I and its signaling pathways, with respect to the cardiovascular system, will aid in the development of novel therapeutics for cardiovascular diseases. In this review, we summarize the structure, activation, signaling pathways, and role of RIG-I in cardiovascular diseases.

Copyright © 2022 Wang, Yin, Gu, Shao, Jia, Chen and Xia.

Address: Department of Clinical Laboratory, Children's Hospital of Nanjing Medical University, Nanjing, China.; Department of Cardiology, Children's Hospital of Nanjing Medical University, Nanjing, China.; School of Pediatrics, Nanjing Medical University, Nanjing, China.; Department of Nephrology, Children's Hospital of Nanjing Medical University, Nanjing, China.; Jiangsu Key Laboratory of Pediatrics, Nanjing Medical University, Nanjing, China.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.